208 related articles for article (PubMed ID: 27517489)
21. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.
Antoon JW; White MD; Meacham WD; Slaughter EM; Muir SE; Elliott S; Rhodes LV; Ashe HB; Wiese TE; Smith CD; Burow ME; Beckman BS
Endocrinology; 2010 Nov; 151(11):5124-35. PubMed ID: 20861237
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
23. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
[TBL] [Abstract][Full Text] [Related]
24. A novel sphingosine kinase inhibitor induces autophagy in tumor cells.
Beljanski V; Knaak C; Smith CD
J Pharmacol Exp Ther; 2010 May; 333(2):454-64. PubMed ID: 20179157
[TBL] [Abstract][Full Text] [Related]
25. Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells.
Kim N; Kang MJ; Lee SH; Son JH; Lee JE; Paik WH; Ryu JK; Kim YT
Anticancer Res; 2018 Jun; 38(6):3527-3533. PubMed ID: 29848706
[TBL] [Abstract][Full Text] [Related]
26. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.
Liu Q; Song C; Li J; Liu M; Fu L; Jiang J; Zeng Z; Zhu H
Med Oncol; 2022 Jun; 39(9):124. PubMed ID: 35716217
[TBL] [Abstract][Full Text] [Related]
27. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
[TBL] [Abstract][Full Text] [Related]
28. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
29. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
Zhou J; Chen J; Yu H
Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Shimizu K; Nishiyama T; Hori Y
Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
[TBL] [Abstract][Full Text] [Related]
31. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
[TBL] [Abstract][Full Text] [Related]
32. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.
Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P
Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390
[TBL] [Abstract][Full Text] [Related]
33. ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2.
Li W; Chen Q; Gao W; Zeng H
Pharmazie; 2022 Sep; 77(7):224-229. PubMed ID: 36199183
[TBL] [Abstract][Full Text] [Related]
34. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
Itoi T; Sofuni A; Fukushima N; Itokawa F; Tsuchiya T; Kurihara T; Moriyasu F; Tsuchida A; Kasuya K
J Gastroenterol; 2007 May; 42(5):389-94. PubMed ID: 17530364
[TBL] [Abstract][Full Text] [Related]
35. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S
Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645
[TBL] [Abstract][Full Text] [Related]
36. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.
Kato T; Ono H; Fujii M; Akahoshi K; Ogura T; Ogawa K; Ban D; Kudo A; Tanaka S; Tanabe M
PLoS One; 2021; 16(6):e0252917. PubMed ID: 34111175
[TBL] [Abstract][Full Text] [Related]
37. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
Jones RJ; Baladandayuthapani V; Neelapu S; Fayad LE; Romaguera JE; Wang M; Sharma R; Yang D; Orlowski RZ
Blood; 2011 Oct; 118(15):4140-9. PubMed ID: 21844567
[TBL] [Abstract][Full Text] [Related]
38. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Liang M; Zhao T; Ma L; Guo Y
Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
[TBL] [Abstract][Full Text] [Related]
39. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
D'Aronzo M; Vinciguerra M; Mazza T; Panebianco C; Saracino C; Pereira SP; Graziano P; Pazienza V
Oncotarget; 2015 Jul; 6(21):18545-57. PubMed ID: 26176887
[TBL] [Abstract][Full Text] [Related]
40. Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression.
Wang C; Zhang W; Fu M; Yang A; Huang H; Xie J
Oncol Rep; 2015 Jan; 33(1):383-90. PubMed ID: 25394408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
